Tissue Regenix (GB:TRX) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Tissue Regenix Group PLC reports a 16% increase in revenues to $16.4 million in H1 2024, with significant growth in their regenerative medical devices driven by BioRinse and dCELL technology platforms. The company has doubled its adjusted EBITDA profit to $1.1 million and maintained a solid cash position, while achieving its eighth consecutive period of growth. The successful results are attributed to strategic growth initiatives, including the expansion of its San Antonio facility, expected to complete in 2025.
For further insights into GB:TRX stock, check out TipRanks’ Stock Analysis page.